Aurinia Pharmaceuticals (AUPH) Change in Receivables (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Change in Receivables data on file, last reported at $7.7 million in Q1 2026.

• Quarterly Change in Receivables rose 102.86% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (down 22.87% YoY) and the FY2025 annual result came in at $4.9 million, down 60.58% from the prior year.
• Change in Receivables eased to $7.7 million in Q1 2026, from $10.7 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $23.6 million in Q3 2022 to a low of -$28.3 million in Q4 2022.
• A 5-year average of $2.0 million and a median of $3.8 million in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2024 — Change in Receivables sank 841.14% — and 2025, when it soared 17483.61%.
• Tracing AUPH's Change in Receivables over 5 years: stood at -$28.3 million in 2022, then soared by 51.01% to -$13.9 million in 2023, then jumped by 100.44% to $61000.0 in 2024, then soared by 17483.61% to $10.7 million in 2025, then dropped by 28.02% to $7.7 million in 2026.
• The last three Change in Receivables figures came in at $7.7 million (Q1 2026), $10.7 million (Q4 2025), and -$9.4 million (Q3 2025), per Business Quant data.